Keros Therapeutics, Inc. (NASDAQ:KROS) Receives $88.29 Consensus Target Price from Brokerages
Keros Therapeutics, Inc. (NASDAQ:KROS – Get Free Report) has received an average rating of “Buy” from the eight brokerages that are currently covering the firm, Marketbeat Ratings reports. Eight analysts have rated the stock with a buy rating. The average twelve-month price objective among analysts that have covered the stock in the last year is […]
More Stories
Is Hell’s Paradise Season 3 Renewed? Release Date, Plot, and Episodes
With the recent release of the anime series Hell’s Paradise, fans are curious to know about the renewal status of...
Who is Lana Condor? Movies and Controversy at the Fashion Trust Awards Show
From an orphanage to becoming a well-known face in the American film industry, Lana has come a long way. Want...
Bridgerton Season 5: Release Date, Cast, Teaser, and Recent Updates
Fans’ favourite series, Bridgerton season 5, is coming back soon. The series’ official network, Netflix, has officially announced the renewal....
CBP to Begin First Phase of Tariff Refunds Following Supreme Court Ruling
By Aldgra Fredly U.S. Customs and Border Protection (CBP) is set to begin the first phase of its refund process...
2 US Embassy Employees, 2 Mexican Officials Killed in Car Crash
By Aldgra Fredly Two instructor officers from the U.S. Embassy in Mexico and two Mexican officials died in a car...
Beyond Hormuz: The US–Indonesia Defense Pact and What It Means for China
By Antonio Graceffo The U.S.–Indonesia defense pact strengthens American strategic control over key maritime chokepoints, enhancing its ability to pressure...